Morgan Stanley analyst Patrick Wood lowered the firm’s price target on Baxter (BAX) to $15 from $19 and keeps an Underweight rating on the shares. Going into 2026, MedTech “looks well-positioned on several fronts” as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for “a solid industry setup,” the analyst tells investors in a note for the group on the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter International Amends Credit Agreement for Flexibility
- Baxter put volume heavy and directionally bearish
- Baxter International Ups Tender Offer to $600 Million
- Baxter International Launches $300M Cash Tender Offers
- Baxter (BAX) Hit with Class Action Lawsuit over Defective Novum LVP Infusion Pumps